SOURCE: The Bedford Report

The Bedford Report

December 08, 2011 08:16 ET

China's Booming Healthcare Sector Poised to Benefit China Medical Technologies and Sinovac Biotech

The Bedford Report Provides Equity Research on China Medical Technologies & Sinovac Biotech

NEW YORK, NY--(Marketwire - Dec 8, 2011) - China's healthcare sector has been on the upswing in recent years with rising incomes and greater government spending on medical care boosting the appeal of several companies in the sector. As The Wall Street Journal reported, "A big part of China's appeal is that it has companies producing drugs and medical devices that are well-positioned to tap the burgeoning domestic market." The Bedford Report examines the outlook for companies in China's Healthcare Sector and provides equity research on China Medical Technologies, Inc. (NASDAQ: CMED) and Sinovac Biotech Ltd. (NASDAQ: SVA). Access to the full company reports can be found at:

www.bedfordreport.com/CMED

www.bedfordreport.com/SVA

To date, more than 1.28 billion Chinese citizens are covered by basic medical insurance programs run by the government, accounting for nearly 96 percent of the population, according to the latest statistics from the Ministry of Health. Vice Premier Li Keqiang said last week that the government is looking at measures that will deepen the reform of China's health care system, including increased allowances and expanding the coverage of the country's essential medicine system.

Keqiang added that health care reform is now facing new challenges during the 12th Five-Year Plan period (2011-2015) due to accelerating urbanization and an aging population.

The Bedford Report releases market research on China's Healthcare Sector so investors can stay ahead of the crowd and make the best investment decisions to maximize their returns. Take a few minutes to register with us free at www.bedfordreport.com and get exclusive access to our numerous analyst reports and industry newsletters.

Sinovac Biotech Ltd., a biopharmaceutical company, engages in the research, development, manufacture, and commercialization of vaccines against the hepatitis A, hepatitis B, and influenza viruses in the People's Republic of China. Last month the company announced that sales in the third quarter increased 60.8% year-over-year to $15.4 million, compared to $9.6 million, and year-to-date sales increased 47.2% to $35.7 million. Dr. Weidong Yin, Chairman, President and CEO of Sinovac, commented, "Our third quarter 2011 sales reflected the continued demand for our hepatitis vaccines, which represent about two-thirds of the sales this quarter."

China Medical Technologies, Inc., a medical device company, develops, manufactures, and markets immunodiagnostic and molecular diagnostic products. Shares of CMED collapsed on Tuesday to hit a new low, after an online research firm, Glaucus Research Group, alleged that the Chinese company had defrauded investors. CMED denies the allegations entirely, arguing that "the allegations set forth in the Glaucus Research report concern matters which have long been disclosed in the Company's annual reports and press releases, misrepresent the information they present and attribute motives to management that are based on innuendo and fail to take into account business and commercial considerations relevant to the matters discussed in the Report."

The Bedford Report provides Market Research focused on equities that offer growth opportunities, value, and strong potential return. We strive to provide the most up-to-date market activities. We constantly create research reports and newsletters for our members. The Bedford Report has not been compensated by any of the above-mentioned companies. We act as an independent research portal and are aware that all investment entails inherent risks. Please view the full disclaimer at: http://www.bedfordreport.com/disclaimer

Contact Information